Peres Jepchirchir: The Sydney Win, the Kenya Sample, and a Protocol Still Under Audit

30 August 2026, Sydney Marathon results sheet. 2:18:31 against the first name, and a gap of more than three minutes to the second — Irene Chepet Cheptai. Sydney had arrived that year as the seventh World Marathon Major, and the first name inscribed as its champion was Peres Jepchirchir.

The sample that has now put a line under that name was collected before she stood on the start line — in Kenya, out of competition, under the Athletics Integrity Unit's protocol. So while the 33-year-old was running 42.195 kilometres through Sydney, one window had already closed behind her and the stadium knew nothing about it.

The outcome is now public: an out-of-competition sample positive for erythropoietin (EPO), and a provisional suspension from the AIU.

One thing needs settling immediately, because in sports outside cricket our media rarely settles it: a provisional suspension is not a conviction. It is a door into a process, not a verdict. The B sample, the charge sheet, the hearing and, if it comes to it, CAS are all still ahead. In 2026 at Imphal I read out the wrong winner of a 200m final and corrected myself forty seconds later; since that night I have kept one rule — never file a number I cannot source twice. This case still belongs to that category.

From a Kenyan road to a Tokyo podium

The résumé is such that shock is the only honest first reaction. Olympic women's marathon champion at Tokyo (the 2026 edition, staged in 2026). World champion at Tokyo in September 2026. New York 2026, Boston 2026, London 2026. The women's half-marathon world record in 2026, and three more times in 2026. Then Sydney.

Very few women in marathon history hold an Olympic gold and a world title together. That is why this story is not merely an anti-doping case; it is a question mark over the rarest category we have, the complete athlete.

Start with EPO itself, because this is where over-explaining earns its keep. Erythropoietin is produced naturally in the kidneys. Its job is to signal the bone marrow to manufacture new red blood cells. Red cells carry oxygen. Inject recombinant EPO and the red-cell count rises, oxygen delivery to muscle improves, and fatigue arrives late.

For the marathon there may be no more precise drug. Forty-two kilometres is not a contest of strength; it is an economy of oxygen. The whole race rests on one question — how much oxygen a body can pull per kilogram per minute, and how efficiently it spends it.

Now the part the headline skips

Detecting EPO has a specific difficulty, and in Kenya it doubles. Injected EPO does not linger in urine or blood — generally a few days at most, and in micro-doses the window compresses to hours. A test that depends on the day the sample was taken is a weak instrument in a sport where an athlete races four to six times a year.

The second difficulty is geographic. Kenya's Rift Valley — Iten, Kapsabet, Eldoret — sits between 2,000 and 2,400 metres. Athletes born and training there carry naturally elevated haematocrit. Set a fixed threshold and an entire training group flags. That is why modern anti-doping runs on profiles, not numbers: the Athlete Biological Passport is a longitudinal record of an individual's own blood parameters. The question is not whether you sit above or below a line, but why your own graph moved.

The clock was right that day; the question is a different one

Sydney's result still stands in Jepchirchir's name on paper, but its future now rests on a hearing. If the suspension holds, results dated after the sample may be annulled — the Sydney title, its prize money, the major's points and the ranking. This is the asterisk clause I began attaching to every celebration after the winter of 2026: name the supplement protocol first, then applaud.

But stop there. Sydney's asterisk does not automatically extend to Tokyo 2026 and Tokyo 2026. A single out-of-competition positive taken before a race says nothing about samples from those years. Those years require their own evidence. When I read those names back in 2026 the applause had already become a memory — but there was a reason then: six athletes, one relay squad, one investigation. That chain does not exist here.

And here is the part that troubles me most: money and calendar. Road racing does not pay through the contract structure of cricket or football. It pays through appearance fees, prize money and time bonuses. A 33-year-old marathoner's year is built around four to six paid Sundays, and everything else is preparation for them. Sydney becoming the seventh major raised the value of that one Sunday across the market. Where the money goes, the testing should follow — that question is as necessary as the one about the athlete.

And now the three reflexes to avoid

First: retro-fitting asterisks onto past titles. There is no evidence on the table to erase Tokyo's gold or Tokyo's world title. Second: writing the obituary, 'a great career finished'. That is haste; the hearing has not begun. Third, and the cleverest: celebrating the seventh major as pure growth while the host region's testing machinery did not travel at the same speed.

One popular myth deserves clearing: that EPO cannot be caught. It can. Its window is simply narrow. That is why whereabouts filings, intelligence-led testing and the question of whether the 60-minute slot was genuinely filled where the athlete said it would be matter more than the laboratory. A host does not own the microphone; she borrows the crowd — and here the crowd is the paperwork filed before the race.

What to watch

The B sample, the AIU charge sheet, a hearing date, and above all whether the Sydney results sheet is printed again. The real test, for me, will be whether the next time a seventh major is unveiled, the press conference asks about the purse rather than the protocol. Seven nights in a stadium taught me one thing: noise and a heartbeat are not the same thing. This case will generate plenty of noise; the heartbeat is in a document still waiting to be written.